Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL Edited by Katie Lennon July 09, 2026 J Clin Oncol. 2026;:JCO2502849. doi:10.1200/JCO-25-02849

https://www.medscape.com/viewarticle/polatuzumab-vedotin-boosts-survival-relapsed-dlbcl-2026a1000naz?src= Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) reduced the risk for death by 40% compared with rituximab, gemcitabine, and oxaliplatin (R-GemOx) alone in patients with transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The combination more than doubles complete response rates from 19.0% to 40.3% and extends median overall survival from 12.5 months to 19.5 months.